Lys Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $5M

  • Investors
  • 9

Lys Therapeutics General Information

Description

Developer of biotherapies designed to treat patients suffering from neurovascular or neurodegenerative disorders. The company's drugs are based on the monoclonal antibody, one protease called tissue plasminogen activator (tPA) that triggers off-target toxicity through hyperactivation of both vascular and neuronal NMDA receptors (NMDAr), enabling healthcare providers to counteract neuroinflammation to tackle neurodegeneration.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 56 rue Saint-Jean-De-Dieu
  • 69007 Lyon
  • France
+33 0
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 56 rue Saint-Jean-De-Dieu
  • 69007 Lyon
  • France
+33 0

Lys Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lys Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Grant 22-Sep-2025 $5M Completed Clinical Trials - General
10. Grant 24-Sep-2024 Completed Clinical Trials - General
9. Early Stage VC 01-Jan-2024 Completed Clinical Trials - General
8. Accelerator/Incubator 01-Jan-2024 Completed Clinical Trials - General
7. Grant 14-Nov-2023 Completed Clinical Trials - General
6. Grant 15-Mar-2023 Completed Clinical Trials - General
5. Seed Round 20-Nov-2022 Completed Clinical Trials - General
4. Grant 15-Oct-2021 Completed Clinical Trials - General
3. Seed Round 01-Jan-2021 Completed Startup
2. Accelerator/Incubator Completed Startup
To view Lys Therapeutics’s complete valuation and funding history, request access »

Lys Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Lys Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Lys Therapeutics Patents

Lys Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260226177-A1 Antibodies for treating neurological and neurovascular disorders Pending 05-Aug-2024
WO-2026033259-A1 Antibodies for treating neurological and neurovascular disorders Pending 05-Aug-2024

Lys Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lys Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Iventure (Grenoble) Accelerator/Incubator
Normandie Participations Venture Capital Minority
Michael J. Fox Foundation Limited Partner
Bpifrance Sovereign Wealth Fund Minority
Health Technology Holding Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Lys Therapeutics FAQs

  • When was Lys Therapeutics founded?

    Lys Therapeutics was founded in 2021.

  • Where is Lys Therapeutics headquartered?

    Lys Therapeutics is headquartered in Lyon, France.

  • What is the size of Lys Therapeutics?

    Lys Therapeutics has 15 total employees.

  • What industry is Lys Therapeutics in?

    Lys Therapeutics’s primary industry is Drug Discovery.

  • Is Lys Therapeutics a private or public company?

    Lys Therapeutics is a Private company.

  • What is Lys Therapeutics’s current revenue?

    The current revenue for Lys Therapeutics is .

  • How much funding has Lys Therapeutics raised over time?

    Lys Therapeutics has raised $5.53M.

  • Who are Lys Therapeutics’s investors?

    Iventure (Grenoble), Normandie Participations, Michael J. Fox Foundation, Bpifrance, and Health Technology Holding are 5 of 9 investors who have invested in Lys Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process